Prothena Corporation PLC to Discuss Results of the Phase 3 VITAL Amyloidosis Study - Conference Call Transcript
Good day, ladies and gentlemen, and welcome to the Phase III VITAL Study Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Ms. Ellen Rose. Ma'am, you may begin.
Thank you, Valerie. Good afternoon, everyone, and welcome to Prothena's investor conference call to review the final results from the Phase III VITAL Amyloidosis Study. Please review the press release we issued earlier today, which is available at our website at prothena.com and is also attached to a Form 8-K that was filed today with the SEC. The slides for this presentation are available in the Investors section of our website and also include Appendix slides with additional detail.
Speaking on today's call, we have Dr. Gene Kinney, our President and Chief Executive Officer, who will provide an overview of the results; Dr. Wagner Zago, our Chief Scientific Officer, will discuss the mechanisms of action and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |